4-1-methyl-1H-imidazol-2-yl-piperidine hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-1-methyl-1H-imidazol-2-yl-piperidine hydrochloride
• 英文别名: 4-(1-methylimidazol-2-yl)piperidine hydrochloride；4-(1-methylimidazol-2-yl)piperidine;hydrochloride
• 化学式: C₉H₁₅N₃*ClH
• 分子量: 201.699
• InChiKey: VBYCEGKVIURLCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Boc-6-氧代-2-氮杂螺[3.3]庚烷 、 4-1-methyl-1H-imidazol-2-yl-piperidine hydrochloride 在 三乙胺 、 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 Tert-butyl 6-[4-(1-methylimidazol-2-yl)piperidin-1-yl]-2-azaspiro[3.3]heptane-2-carboxylate
  参考文献：
  名称：

  [EN] MUSCARINIC AGONISTS
  [FR] AGONISTES MUSCARINIQUES

  摘要：

  公开号：

  WO2017021728A9
• 作为产物：
  描述：

  tert-butyl 4-(1-methyl-1H-imidazol-2-yl)piperidine-1-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 3.0h， 生成 4-1-methyl-1H-imidazol-2-yl-piperidine hydrochloride
  参考文献：
  名称：

  Discovery of Imidazo[1,5-c]imidazol-3-ones: Weakly Basic, Orally Active Factor Xa Inhibitors

  摘要：

  The coagulation enzyme factor Xa (FXa) has been recognized as a promising target for the development of new antithrombotic agents. We previously found compound I to be an orally bioavailable FXa inhibitor in fasted monkeys; however, I showed poor bioavailability in rats and fed monkeys. To work out the pharmacokinetic problems, we focused our synthetic efforts on the chemical conversion of the 4-(imidazo[1,2-a]pyridin-5-yl)piperazine moiety of 1 to imidazolylpiperidine derivatives (fused and nonfused), which resulted in the discovery of the weakly basic imidazo[1,5-c]imidazol-3-one 3q as a potent and selective FXa inhibitor. Compound 3q showed favorable oral bioavailability in rats and monkeys under both fasted and fed conditions and antithrombotic efficacy in a rat model of venous thrombosis after oral administration, without a significant increase in bleeding time (unlike warfarin). On the basis of these promising properties, compound 3q was selected for further evaluation.

  DOI：

  10.1021/jm701548u

文献信息

• [EN] PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES DE PIPÉRIDIN-1-YLE ET D'AZÉPIN-1-YLE À TITRE D'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014122474A1

  公开（公告）日：2014-08-14

  The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

  本发明提供了式（I）的肌氨酸M4受体激动剂及其药用盐，其中m、n、p、q、R、R2和R3如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗精神分裂症、阿尔茨海默病和各种认知障碍以及治疗或缓解疼痛中的用途。
• PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150376179A1

  公开（公告）日：2015-12-31

  The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R 2 and R 3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

  本发明提供公式（I）及其药学上可接受的盐的毛果碱M4受体激动剂，其中m，n，p，q，R，R2和R3如规范中所定义，其制备过程，含有它们的药物组合物以及它们在治疗诸如精神分裂症，阿尔茨海默病和各种认知障碍以及治疗或缓解疼痛方面的用途。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3406609A1

  公开（公告）日：2018-11-28

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1b or a salt thereof, wherein Q, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括符合式 1b 的化合物 或其盐，其中 Q、R3 和 R4 如本文所定义。
• Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
  申请人：Heptares Therapeutics Limited

  公开号：US10030012B2

  公开（公告）日：2018-07-24

  The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

  本发明提供了式 (I) 的毒蕈碱类 M4 受体激动剂及其药学上可接受的盐（其中 m、n、p、q、R、R2 和 R3 如说明书中所定义）、其制备工艺、含有它们的药物组合物以及它们在治疗诸如精神分裂症、阿尔茨海默病和各种认知障碍等疾病以及治疗或减轻疼痛中的用途。
• Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
  申请人：Heptares Therapeutics Limited

  公开号：US10196380B2

  公开（公告）日：2019-02-05

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。